WCLC 2022 Conference Coverage


 

WCLC 2022 on the ADAURA2 Phase III Study: Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFRm NSCLC

63 views
September 7, 2022
Comments 0
Login to view comments. Click here to Login